A RNA-DNA Hybrid Aptamer for Nanoparticle-Based Prostate Tumor Targeted Drug Delivery

Leach, John C.; Wang, Andrew; Ye, Kaiming; Jin, Sha

doi:10.3390/ijms17030380

Cited by 60 publications

(22 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the most recent advances, cancer treatments, such as chemotherapy and radiotherapy, still have significant limitations regarding side effects, the major one being, of course, damage to healthy cells. Consequently, cancer treatments with minimal drug and radiation doses have been in the spotlight [ 89 ] due to the fact that they (attempt to) target, specifically, non-healthy cells. Some cell receptors expressed in normal cells are overexpressed in cancer cells; thus, efficiency could be enhanced whilst minimizing the damage to normal cells [ 90 ].…”

Section: Aptamers As Chemotherapy Agentsmentioning

confidence: 99%

Aptamers: novelty tools for cancer biology

et al. 2018

View full text Add to dashboard Cite

Although the term ‘cancer’ was still over two thousand years away of being coined, the first known cases of the disease date back to about 3000BC, in ancient Egypt. Five thousand years later, still lacking a cure, it has become one of the leading causes of death, killing over half a dozen million people yearly. So far, monoclonal antibodies are the most successful immune-therapy tools when it comes to fighting cancer. The number of clinical trials that use them has been increasing steadily during the past few years, especially since the Food and Drug Administration greenlit the use of the first immune-checkpoint blockade antibodies. However, albeit successful, this approach does come with the cost of auto-inflammatory toxicity. Taking this into account, the development of new therapeutic reagents with low toxicity becomes evident, particularly ones acting in tandem with the tools currently at our disposal. Ever since its discovery in the early nineties, aptamer technology has been used for a wide range of diagnostic and therapeutic applications. With similar properties to those of monoclonal antibodies, such as high-specificity of recognition and high-affinity binding, and the advantages of being developed using in vitro selection procedures, aptamers quickly became convenient building blocks for the generation of multifunctional constructs. In this review, we discuss the steps involved in the in vitro selection process that leads to functional aptamers - known as Systematic Evolution of Ligands by Exponential Enrichment - as well as the most recent applications of this technology in diagnostic and treatment of oncological illnesses. Moreover, we also suggest ways to improve such use.

show abstract

Section: Aptamers As Chemotherapy Agentsmentioning

confidence: 99%

Aptamers: novelty tools for cancer biology

et al. 2018

View full text Add to dashboard Cite

show abstract

“…A DNA-RNA hybrid aptamer targeting PSMA was instead used to functionalize, via biotin-streptavidin coupling, SPIONPs loaded with DOX. The resulting SPIO-Apt-Dox was effectively employed as a specific delivery platform for prostate cancer therapy [74]. …”

Section: Aptamer-nanoparticles Systemsmentioning

confidence: 99%

Aptamer-Mediated Targeted Delivery of Therapeutics: An Update

2016

View full text Add to dashboard Cite

The selective delivery of drugs in a cell- or tissue-specific manner represents the main challenge for medical research; in order to reduce the occurrence of unwanted off-target effects. In this regard, nucleic acid aptamers have emerged as an attractive class of carrier molecules due to their ability to bind with high affinity to specific ligands; their high chemical flexibility; as well as tissue penetration capability. To date, different aptamer-drug systems and aptamer–nanoparticles systems, in which nanoparticles function together with aptamers for the targeted delivery, have been successfully developed for a wide range of therapeutics, including toxins; peptides; chemotherapeutics and oligonucleotides. Therefore, aptamer-mediated drug delivery represents a powerful tool for the safe and effective treatment of different human pathologies, including cancer; neurological diseases; immunological diseases and so on. In this review, we will summarize recent progress in the field of aptamer-mediated drug delivery and we will discuss the advantages, the achieved objectives and the challenges to be still addressed in the near future, in order to improve the effectiveness of therapies.

show abstract

“…Huang et al (2008) demonstrated that ∼80 aptamers could be linked covalently to the surface of Au-Ag nanorods using thiolated functional groups on the aptamers. Recent studies have attested to the therapeutic success of aptamer-nanoparticle conjugates with higher efficiencies (Azhdarzadeh et al 2016;Hong et al 2016;Leach et al 2016;Liu et al 2016). These interesting studies include antiepithelial cell adhesion molecule aptamermediated detection of cancer biomarkers at the level of femtomoles (Hong et al 2016).…”

Section: Aptamer-conjugated Nanoparticlesmentioning

confidence: 99%

Cell-targeting aptamers act as intracellular delivery vehicles

Gopinath

Lakshmipriya

Chen

et al. 2016

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

Aptamers are single-stranded nucleic acids or peptides identified from a randomized combinatorial library through specific interaction with the target of interest. Targets can be of any size, from small molecules to whole cells, attesting to the versatility of aptamers for binding a wide range of targets. Aptamers show drug properties that are analogous to antibodies, with high specificity and affinity to their target molecules. Aptamers can penetrate disease-causing microbial and mammalian cells. Generated aptamers that target surface biomarkers act as cell-targeting agents and intracellular delivery vehicles. Within this context, the "cell-internalizing aptamers" are widely investigated via the process of cell uptake with selective binding during in vivo systematic evolution of ligands by exponential enrichment (SELEX) or by cell-internalization SELEX, which targets cell surface antigens to be receptors. These internalizing aptamers are highly preferable for the localization and functional analyses of multiple targets. In this overview, we discuss the ways by which internalizing aptamers are generated and their successful applications. Furthermore, theranostic approaches featuring cell-internalized aptamers are discussed with the purpose of analyzing and diagnosing disease-causing pathogens.

show abstract

A RNA-DNA Hybrid Aptamer for Nanoparticle-Based Prostate Tumor Targeted Drug Delivery

Cited by 60 publications

References 39 publications

Aptamers: novelty tools for cancer biology

Aptamers: novelty tools for cancer biology

Aptamer-Mediated Targeted Delivery of Therapeutics: An Update

Cell-targeting aptamers act as intracellular delivery vehicles

Contact Info

Product

Resources

About